Vanguard Global Advisers’s Bionano Genomics BNGO Stock Holding History

Vanguard Global Advisers’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-173	Closed	-$202	–	3655
2026 Q1	$202	Buy	+173	New	+$222	﹤0.01%	3670

Other funds holding BNGO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

CAM

Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Global Advisers's BNGO Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Bionano Genomics (BNGO) in Q2 2026, closing a stake of 173 shares — an estimated $202 sold.

Vanguard Global Advisers first reported a position in BNGO in Q1 2026 and held it in 1 quarter. The position peaked at $202 in Q1 2026. 34 funds tracked by Wall St. Rank hold BNGO as of Q2 2026.

Vanguard Global Advisers reported no remaining Bionano Genomics position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 173 Bionano Genomics shares in Q2 2026, an estimated $202.
Vanguard Global Advisers first reported a position in Bionano Genomics in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's Bionano Genomics position peaked at $202 in Q1 2026.
34 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.